Patents Issued in October 26, 2017
  • Publication number: 20170304309
    Abstract: The present invention relates to caffeine for use in the treatment of myotonic dystrophy type 1 and type 2. The present invention also relates to compositions comprising caffeine for use in the treatment of myotonic dystrophy type 1 and type 2.
    Type: Application
    Filed: November 13, 2015
    Publication date: October 26, 2017
    Inventors: Ruben ARTERO ALLEPUZ, Josep CASTELLS BOLIART, José Ignacio BORRELL BILBAO, Beatriz LLAMUSI TROÍSI, Ariadna BARGIELA SCHÖNBRUNN, Piotr KONIECZNY, Marta PASCUAL GILABERT, Jordi TEIXIDÓ CLOSA, Roger ESTRADA TEJEDOR, Alejandro LÓPEZ GONZÁLEZ
  • Publication number: 20170304310
    Abstract: The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels.
    Type: Application
    Filed: July 10, 2017
    Publication date: October 26, 2017
    Inventors: Kun Ping LU, Matthew Brian BOXER, Mindy Irene Emily DAVIS, Rajan PRAGANI, Min SHEN, Anton Momtchilov SIMEONOV, Shuo WEI, Xiao Zhen ZHOU
  • Publication number: 20170304311
    Abstract: A pharmaceutical combination comprising: (a) a phosphatidylinositol-3-kinase inhibitor selected from 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine, (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or any pharmaceutically acceptable salt thereof and (b) a gonadorelin agonist and, optionally, (c) an antiestrogen agent, particularly for use in the treatment or prevention of a cancer; uses of such a combination in the preparation of a medicament for the treatment or prevention of a cancer; pharmaceutical compositions of the combination of said therapeutic agents and methods of treating a cancer in a subject comprising administering to said subject a therapeutically effective amount of such a combination.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Applicant: NOVARTIS AG
    Inventors: Samit Hirawat, Cristian Massacesi
  • Publication number: 20170304312
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: June 21, 2017
    Publication date: October 26, 2017
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • Publication number: 20170304313
    Abstract: This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or preventing a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.
    Type: Application
    Filed: October 2, 2015
    Publication date: October 26, 2017
    Inventors: Dale Porter, Nafeeza Hafeez
  • Publication number: 20170304314
    Abstract: The present invention relates to a dosage regimen of ST10 (ferric maltol) for use in the treatment of patients suffering from iron deficiency with or without anaemia. The invention specifically relates to use of ST10 wherein the dose is between 40 mg and 90 mg twice daily.
    Type: Application
    Filed: October 21, 2015
    Publication date: October 26, 2017
    Inventors: Nicholas Mallard, Carl Andrew Sterritt, Julian David Howell
  • Publication number: 20170304315
    Abstract: Provided are methods for the combined use of cyclin-dependent kinase 9 (CDK9) inhibitors and bromodomain containing 4 (BRD4) inhibitors to reduce, inhibit and/or prevent cartilage degradation and systemic traumatic inflammation. A combination of CDK9 inhibitors and BRD4 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. A combination of CDK9 inhibitors and BRD4 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.
    Type: Application
    Filed: October 13, 2015
    Publication date: October 26, 2017
    Applicant: The Regents of the University of California
    Inventors: Dominik HAUDENSCHILD, Jasper YIK
  • Publication number: 20170304316
    Abstract: Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof. The present invention further relates to the composition(s) manufactured by the process described herein and methods for treating persons suffering from glaucoma or ocular hypertension. In particular, the persons are treated with carbonic anhydrase inhibitor(s) alone or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents to control their intraocular pressure (IOP).
    Type: Application
    Filed: October 16, 2015
    Publication date: October 26, 2017
    Inventors: Mandar V. Shah, Deepak Bahri
  • Publication number: 20170304317
    Abstract: A compound is provided for oral administration of dehydroepiandrosterone (DHEA) derivatives to a human so as to improve at least one of adrenal hormonal balance, improved immune system function, reduction of adipose tissue, skeletal muscle growth, reduction of abdominal bloating, improved recovery from training, increased strength, and increased endurance. The compound includes a first portion comprised of any one of 3a-enanthoxy-5a-androstan-17-one, 3b-undecyloxy-5a-androstan-17-one, and 3b-hydroxy-androstane-3b-ol-one. A second portion of the compound is comprised of 6,7-dihydrogergamottin. A third portion is comprised of piperine, and a fourth portion is comprised of any one or more of rice flour, gelatin, magnesium stearate, and silica. The compound preferably is administered in capsule form one or two times in a 24-hour period.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Inventor: Robert DiMaggio
  • Publication number: 20170304318
    Abstract: The present invention provides certain cortexolone derivatives of formula (I) and the same for use as antitumor active ingredients for the curative or adjuvant, or neoadjuvant or palliative treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, including malignant neoplasias and metastasis. Another aspect of the invention relates to pharmaceutical compositions comprising cortexolone derivatives of formula (I) as active ingredients and at least one physiologically acceptable excipient, and to the use of said pharmaceutical compositions as antitumor medicinal products.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Applicant: COSMO TECHNOLOGIES LTD.
    Inventor: Mara GERLONI
  • Publication number: 20170304319
    Abstract: The present invention relates to an oral film consisting essentially of dexamethasone and hydroxypropyl methylcellulose, wherein the concentration of dexamethasone is 30% w/w or more and the concentration of hydroxypropyl methylcellulose is between 35 and 70% w/w based on total dry matter.
    Type: Application
    Filed: November 4, 2015
    Publication date: October 26, 2017
    Applicants: ACUCORT AB, LTS LOHMANN THERAPIE-SYSTEME AG
    Inventor: Bengt Arvid WESTRIN
  • Publication number: 20170304320
    Abstract: An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Inventors: Nathan Dormer, Cory Berkland
  • Publication number: 20170304321
    Abstract: Methods for treating a subject suffering from a sterol synthesis disorder or a sterol deficiency disorder, e.g., Smith-Lemli-Opitz syndrome, the method comprising administering to the subject an effective amount of an NMDA receptor modulating compound, are provided.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Inventors: Michael C. Quirk, James J. Doherty, Cabriel Martinez Botella
  • Publication number: 20170304322
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
  • Publication number: 20170304323
    Abstract: The invention relates to tablet comprising granules dispersed in at least one hydrophilic compound or matrix. The granules contain an active agent, at least one amphiphilic compound and at least one lipophilic compound. The tablet may include a gastro-resistant film coating.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Applicant: COSMO TECHNOLOGIES LIMITED
    Inventors: Roberto VILLA, Massimo PEDRANI, Mauro AJANI, Lorenzo FOSSATI
  • Publication number: 20170304324
    Abstract: A method of obtaining vitamin D from shiitake includes a) adding ethanol to shiitake powder, followed by reflux extraction, to prepare a shiitake extract; and (b) irradiating ultraviolet (UV) light to the shiitake extract prepared in step (a). When shiitake extracts are obtained and exposed to ultraviolet light under specific conditions, the content of vitamin D2 in the shiitake extracts may be increased.
    Type: Application
    Filed: October 20, 2015
    Publication date: October 26, 2017
    Inventors: Kyung-Je KIM, Kyoung Sun SEO, Tae-Young PARK, Seong-Woo JIN, Bong-Suk CHOI, Jin-Kyeong KIM
  • Publication number: 20170304325
    Abstract: A composition for treating chronic inflammation, including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D in synergistically effective amounts. A method of treating chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and treating chronic inflammation. A method of reducing and/or eliminating symptoms of chronic inflammation, by administering a synergistically effective amount of a composition including an antibiotic, a lipophilic potentiating agent, a guanosine analog antiviral agent, and Vitamin D to an individual suffering from chronic inflammation, and reducing and/or eliminating the individual's symptoms of chronic inflammation.
    Type: Application
    Filed: December 13, 2016
    Publication date: October 26, 2017
    Inventors: Fabrizio De Silvestri, Edoardo Romani
  • Publication number: 20170304326
    Abstract: The purpose of the present invention is to identify a migratory factor that guides pluripotent stem cells (Muse cells) useful in new medical applications to damage, and to provide a pharmaceutical composition that includes the migratory factor for promoting tissue regeneration in regenerative medicine that makes use of Muse cells. In the present invention, a receptor that is specifically expressed in Muse cells rather than non-Muse cells was identified, and it was confirmed that a ligand for this receptor can function as a migratory factor. In the present invention, sphingosine-1-phosphate (S1P) was identified as a migratory factor, and thus, the present invention pertains to a pharmaceutical composition for guiding pluripotent stem cells to damage, the composition including S1P as an active ingredient.
    Type: Application
    Filed: July 6, 2017
    Publication date: October 26, 2017
    Applicants: CLIO, INC., TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY
    Inventors: Mari Dezawa, YOSHINORI FUJIYOSHI, MASANORI YOSHIDA
  • Publication number: 20170304327
    Abstract: Provided are certain methods useful in the treatment of cancer comprising administering a compound of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor;
    Type: Application
    Filed: February 8, 2017
    Publication date: October 26, 2017
    Inventors: Jayant Thatte, Anthony C. Blackburn, Sangdon Han, Robert M. Jones, Jae-Kyu Jung, Antonio Garrido Montalban, Biman B. Pal, Jaimie Karyn Rueter, Sonja Strah-Pleynet, Lars Thoresen, Yifeng Xiong, Dawei Yue, Xiuwen Zhu
  • Publication number: 20170304328
    Abstract: This present invention relates to pharmaceutical compositions comprising cyclophosphamide alone and/or in combination with one or more pharmaceutical active ingredients and one or more pharmaceutically acceptable excipients wherein the cyclophosphamide has D90 particle size less than 100 microns.
    Type: Application
    Filed: September 25, 2015
    Publication date: October 26, 2017
    Inventors: Priyank PATEL, Mayur PATEL, Mahendra PATEL, Balvir SINGH, Ashish SEHGAL
  • Publication number: 20170304329
    Abstract: A method of treating bladder cancer is provided. The method of treating bladder cancer can include: providing a pharmaceutical composition having ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug having a structure of one of the formulae provided herein or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof; and administering the pharmaceutical composition to a subject having the bladder cancer. The ciclopirox or ciclopirox olamine or a ciclopirox-POM prodrug can be administered in a therapeutically effective amount.
    Type: Application
    Filed: November 10, 2015
    Publication date: October 26, 2017
    Inventors: SCOTT J WEIR, SHRIKANT ANANT
  • Publication number: 20170304330
    Abstract: The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 26, 2017
    Inventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
  • Publication number: 20170304331
    Abstract: Osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Inventor: Herriot Tabuteau
  • Publication number: 20170304332
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: July 12, 2017
    Publication date: October 26, 2017
    Inventors: Alaric J. Dyckman, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • Publication number: 20170304333
    Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.
    Type: Application
    Filed: January 5, 2017
    Publication date: October 26, 2017
    Applicants: Emergent Virology LLC, THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
    Inventors: Urban RAMSTEDT, Brennan KLOSE, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Publication number: 20170304334
    Abstract: It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of decubitus in a state in which a defect extending to the dermis, subcutaneous tissue, muscle or bone occurs, it is possible to treat critical skin ulcers such as intractable decubitus ulcers with pockets and huge intractable decubitus ulcers, as well as to treat not only relatively mild decubitus classified as stage II according to the US National Pressure Ulcer Advisory Panel (NPUAP) staging system, i.e.
    Type: Application
    Filed: June 19, 2015
    Publication date: October 26, 2017
    Inventor: Hideyasu Takata
  • Publication number: 20170304335
    Abstract: The present invention relates to pharmaceutical compositions containing steviol glycoside and or steviol glycoside derivatives as well as to their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.
    Type: Application
    Filed: October 28, 2015
    Publication date: October 26, 2017
    Applicant: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Abelardo Isaac AGUILERA PERALTA, Manuel LOPEZ-CABRERA, Rafael SELGAS GUTIERREZ, Sonja STEPPAN, Jutta PASSLICK-DEEJEN
  • Publication number: 20170304336
    Abstract: A combination comprising: (a) a glycyrrhizin derivative; and (b) a hypolipidemic drug; is disclosed. Pharmaceutical compositions, kits, methods of treatment and medical uses of the combination are also disclosed.
    Type: Application
    Filed: October 30, 2015
    Publication date: October 26, 2017
    Inventor: Aleksander Vladimirovich DIKOVSKIY
  • Publication number: 20170304337
    Abstract: The present invention relates to a prodrug of 5-azacytidine or 2?-deoxy-5-azacytidine having remarkable stability against cytidine deaminase, a metabolic hydrolyzing enzyme in replacement of current injections (5-azacytidine or 2?-deoxy-5-azacytidine) which are clinically used as therapeutic agents for various myelomas including myelodysplastic syndrome. The present invention provides a compound represented by formula (1), or salt thereof, wherein, R is OR3 or a hydrogen atom, R1, R2, and R3 are each independently hydrogen atom or silyl group represented by formula (2): wherein, R1, R5, and R6 are each independently alkyl group which may have a substituent, aryl group which may have a substituent, or arylalkyl group which may have a substituent, with the provision that R1, R2, and R3 are not hydrogen atom simultaneously.
    Type: Application
    Filed: November 18, 2016
    Publication date: October 26, 2017
    Applicant: OHARA PHARMACEUTICAL CO., LTD.
    Inventors: Magoichi SAKO, Shinpei SUGIYAMA
  • Publication number: 20170304338
    Abstract: Compositions are provided including nicotinic acid riboside (“NAR”), and derivatives thereof including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-nicotinic acid (“NAR triacetate” or “NARTA”); or derivatives of a reduced form of nicotinic acid riboside (“NARH”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinic acid (“NARH triacetate” or “NARH-TA”); or derivatives of nicotinamide riboside (“NR”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-nicotinamide (“NR triacetate” or “NRTA”); derivatives of a reduced form of nicotinamide riboside (“NRH”), including 1-(2?,3?,5?-triacetyl-beta-D-ribofuranosyl)-1,4-dihydronicotinamide (“NRH triacetate” or “NRH-TA”); or salts or prodrugs thereof, for use in food or beverage applications, pharmaceutical formulations, or as a dietary supplement.
    Type: Application
    Filed: April 20, 2017
    Publication date: October 26, 2017
    Applicant: Chromadex Inc.
    Inventors: Ryan Dellinger, Troy Rhonemus, Mark Morris, Aron Erickson, Hadi Casser, Marie Eugenie Migaud
  • Publication number: 20170304339
    Abstract: The present invention relates to compositions and methods of treating lysosomal storage diseases and methods of using trehalose.
    Type: Application
    Filed: April 21, 2017
    Publication date: October 26, 2017
    Inventor: Marco Sardiello
  • Publication number: 20170304340
    Abstract: A method of treating and/or preventing atopic dermatitis is described. The method includes use of a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: July 12, 2017
    Publication date: October 26, 2017
    Inventors: Feriel HACINI-RACHINEL, Emmanuel VIAL, André JOMARD
  • Publication number: 20170304341
    Abstract: Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis.
    Type: Application
    Filed: July 12, 2017
    Publication date: October 26, 2017
    Applicant: Indena S.p.A.
    Inventors: Ezio Bombardelli, Paolo Morazzoni
  • Publication number: 20170304342
    Abstract: Provided are knottin-drug conjugates. The conjugates include a knottin peptide that includes an engineered loop that binds to a target on a cancer cell surface, and a drug (e.g., a nucleoside drug) conjugated to the knottin peptide through a linker. Also provided are pharmaceutical compositions and kits that include the knottin-drug conjugates, as well as methods of using the knottin-drug conjugates, e.g., for therapeutic purposes.
    Type: Application
    Filed: March 14, 2017
    Publication date: October 26, 2017
    Inventors: Nicholas COX, Jennifer R. COCHRAN, Mark SMITH, James R. KINTZING
  • Publication number: 20170304343
    Abstract: This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.
    Type: Application
    Filed: September 30, 2015
    Publication date: October 26, 2017
    Inventors: Andrew BUCHANAN, Matthieu CHODORGE, Peter CARIUK, Johanna HUSMARK, Clare BALENDRAN, Deepesh PANDEY, Fumin CHANG, Daniel E. BERKOWITZ, Lewis H. ROMER
  • Publication number: 20170304344
    Abstract: The present invention provides compositions methods for treating susceptible viral infections, especially hepatitis C viral (HCV) infections as well as co infections of HCV with other viruses such as HBV and/or HIV. In one embodiment, the present invention provides compositions having the formula (I) and their use in treating viral infections: or a pharmaceutically acceptable salt, ester, stereoisomer, tautomers, solvate, prodrug, or combination thereof.
    Type: Application
    Filed: December 2, 2016
    Publication date: October 26, 2017
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Publication number: 20170304345
    Abstract: The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Panna DUTTA, Adel RAFAI FAR, Min DING, Rajeshwar MOTHERAM
  • Publication number: 20170304346
    Abstract: Disclosed is use of nicotinamide adenine dinucleotide (NADH) or a salt thereof in the preparation of drugs or health-care products for treating phenylketonuria (PKU), wherein a single dose of the NADH or a salt thereof is 1-100 mg.
    Type: Application
    Filed: June 9, 2017
    Publication date: October 26, 2017
    Inventors: Rongzhao FU, Qi ZHANG, Yuemei LIU
  • Publication number: 20170304347
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Application
    Filed: April 19, 2017
    Publication date: October 26, 2017
    Applicant: Julius-Maximilians-Universitat Wurzburg
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • Publication number: 20170304348
    Abstract: The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway.
    Type: Application
    Filed: June 16, 2017
    Publication date: October 26, 2017
    Applicants: INTERNA TECHNOLOGIES B.V., KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN
    Inventors: Eugene Berezikov, Jos Bernard Poell, Willemijn Maria Gommans, Rick Jan van Haastert, Andreas Alphons F.L. van Puijenbroek, Roeland Quirinus Jozef Schaapveld, Gregoire Pierre Andre Prevost
  • Publication number: 20170304349
    Abstract: Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (IISCT), more preferably allogeneic hernatopoietic stein cell transplantation. Graft versus Host Disease oldie invention (GVHD) can be acute aGVHD and/or chronic cOVHD, preferably acute.
    Type: Application
    Filed: July 10, 2017
    Publication date: October 26, 2017
    Inventor: Massimo IACOBELLI
  • Publication number: 20170304350
    Abstract: The invention concerns a pharmaceutical composition for treating a viral infection caused by a member of the Reoviridae family; a method of treatment involving the use of same and use of the anti-viral to treat said viral infection. The agent has use in both humans and animals.
    Type: Application
    Filed: October 7, 2015
    Publication date: October 26, 2017
    Applicant: London School of Hygiene & Tropical Medicine
    Inventor: Polly Roy
  • Publication number: 20170304351
    Abstract: The invention relates to methods, uses and compositions for treating non-infectious diseases with a therapeutically effective amount of a pharmaceutical composition comprising methylsulfonylmethane, glucosamine, L-glycine, and vitamin B12 (or a derivative of any one thereof).
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Applicant: EaglePharma Pty Ltd
    Inventor: Paul TURNER
  • Publication number: 20170304352
    Abstract: Particulate ?-glucan is solubilized at elevated pressure and temperature to form soluble ?-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent.
    Type: Application
    Filed: February 21, 2017
    Publication date: October 26, 2017
    Inventors: Andrew MAGEE, James ROLKE, Ren-der YANG
  • Publication number: 20170304353
    Abstract: An object of the present invention is to provide a carbohydrate-derived energy supplying agent having slow digestibility and sustained digestibility functions. According to the present invention, there is provided a slowly digestible, sustained-type energy supplying agent comprising a saccharide composition which satisfies the following (A), (B), (C), and (D): (A) a percentage of ?-1,6 bonds relative to all glycosidic bonds is 60% or more; (B) a content of saccharides having a degree of polymerization of 1 and 2 relative to all saccharides is 9 mass % or less; (C) a content of saccharides having a degree of polymerization within a range of 3 to 30 relative to all saccharides is 41 mass % or more; and (D) a content of saccharides having a degree of polymerization of 31 or more relative to all saccharides is 50 mass % or less.
    Type: Application
    Filed: September 18, 2015
    Publication date: October 26, 2017
    Inventors: Kenta Aizawa, Kazuki Sekikya, Takahisa Iizuka, Hiroki Takagi, Masayasu Takada, Koichi Ogawa, Hirofumi Sonoki, Akayo Ito, Eri Kokubo
  • Publication number: 20170304354
    Abstract: This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.
    Type: Application
    Filed: March 13, 2017
    Publication date: October 26, 2017
    Applicant: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Serglo Finkielsztein
  • Publication number: 20170304355
    Abstract: Described herein are methods for treating or preventing a disease or disorder of the pulmonary system (e.g., cystic fibrosis), respiratory or digestive system in a subject, the methods comprising administering compounds or compositions comprising water soluble polyglucosamine and derivatized polyglucosamine.
    Type: Application
    Filed: September 11, 2015
    Publication date: October 26, 2017
    Applicant: SYNEDGEN, INC.
    Inventors: Shenda Baker, William P. Wiesmann, Stacy Marie Townsend
  • Publication number: 20170304356
    Abstract: The present invention provides a method of treating constipation and compositions useful in said method. The method comprises administering to a subject in need thereof an effective amount of a crosslinked carboxymethylcellulose having high elastic modulus coupled with high absorbance capacity when swollen in simulated gastric fluid/water (1:8) and simulated intestinal fluids.
    Type: Application
    Filed: April 24, 2017
    Publication date: October 26, 2017
    Inventors: Alessandro Sannino, Christian Demitri, Yishai Zohar, Eyal S. Ron, Barry J. Hand, Cosimo Saponaro
  • Publication number: 20170304357
    Abstract: A composition of chlorine-free poly-oxygenated aluminum hydroxide that comprises a clathrate containing oxygen gas molecules and a nutraceutical. In one embodiment, the poly-oxygenated aluminum hydroxide has particles having a diameter of 212 ?m or less. The nutraceutical may include one or more of a protein, vitamin, fiber, mineral and electrolytes. The composition may be in a powder or fluid form.
    Type: Application
    Filed: July 12, 2017
    Publication date: October 26, 2017
    Inventors: John W Woodmansee, JR., Robert A Woodmansee, Erica D Bruce
  • Publication number: 20170304358
    Abstract: The present invention relates to use of very low dose lithium for primary and secondary prevention of dementia-related disorders and suicide.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 26, 2017
    Inventor: Seyyed Nassir GHAEMI